220827-74-7

Upstream product

• 609-06-3 L-xylose 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 220827-73-6 5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-α-L-xylofuranose 
• 131156-47-3 (3aS,3bR,7aS,8aS)-2,2,5,5-tetramethyltetrahydro-3aH-[1,3]dioxolo[4',5':4,5]furo[3,2-d][1,3]dioxane 
• 114861-22-2 1,2-O-isopropylidene-α-L-xylofuranose 

Downstream Products

• 377085-05-7 [(3aS,5R,6S,6aS)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl]-methanol 
• 377085-07-9 C₂₃H₂₄O₇ 
• 220827-75-8 5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-α-L-ribofuranose 

Relevant academic research and scientific papers

Synthesis of novel D- and L-3′-deoxy-3′-C-Hydroxymethyl nucleoside with exocyclic methylene as potential ribonucleotide reductase inhibitor

D- and L-3′-Deoxy-3′-C-hydroxymethyl thymidine substituted with exocyclic methylene at 2′-position were synthesized, starting from D- and L-xylose as potential ribonucleotide reductase inhibitor, respectively, but they were found to be inactive against several tumor cell lines.

L-Ribonucleosides from L-xylose

L-Xylose was converted into a L-ribose derivative via an oxidation/reduction procedure. The L-ribosyl donor was submitted to a glycosidation reaction according to Vorbruggen's conditions to give L- ribonucleosides (L-uridine, L-cytidine, L-adenosine and L-guanosine) in high yield.